Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | FPR2 | P25090 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4570484 | 0.84 | TSHR (0.45) | LMNAFPR2HTTMAPTALDH1A1 | |
| SCHEMBL7405910 | 0.78 | HMGCR (0.45) | ALDH1A1ALOX15HSD17B10 | |
| SCHEMBL7405906 | 0.78 | HMGCR (0.45) | ALDH1A1ALOX15HSD17B10 | |
| SCHEMBL3409801 | 0.77 | LMNA (0.50) | LMNAFPR2EPHX2HTTMAPT | |
| SCHEMBL3411217 | 0.74 | LMNA (0.47) | LMNAEPHX2HTTMAPTMAPK1 | |
| SCHEMBL25277134 | 0.73 | HMGCR (0.51) | ALDH1A1ALOX15HSD17B10 | |
| SCHEMBL13305477 | 0.73 | TSHR (0.41) | LMNAHTTMAPTALDH1A1GAA | |
| SCHEMBL3342037 | 0.73 | TSHR (0.41) | LMNAHTTMAPTALDH1A1GAA | |
| SCHEMBL25277135 | 0.73 | HMGCR (0.51) | ALDH1A1ALOX15HSD17B10 | |
| SCHEMBL131029 | 0.72 | LMNA (0.61) | LMNAEPHX2MAPTMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315447-B2 | Compositions and methods for the treatment of inflammation | A.T. Resolve Sarl (CH) | 2016-04-19 | — | — | US | disclosed |
| US-20140275247-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | A.T. Resolve Sarl (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8673881-B2 | Compositions and methods for the treatment of inflammation | A.T. Resolve Sarl (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20120101061-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | A.T. Resolve Sarl (CH) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101061-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | ALOX15B, ALOX5, ALOX12 | LMNA 1331/4885FPR2 22/4885EPHX2 64/4885 |
| US-20140275247-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | ALOX15B, ALOX5, ALOX12 | LMNA 1331/4885FPR2 22/4885EPHX2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.